- Article Discussing Analgesic Efficacy of Labopharm's Once-Daily Tramadol
Published in Journal of Pain and Symptom Management - - Company Secures Marketing Partner for Once-Daily Tramadol in Israel -
LAVAL, QC, Sept. 14 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that it will present a poster discussing the ability of its once-daily formulation of tramadol to rapidly attain therapeutic plasma levels and provide quick onset of clinically significant analgesia at the XXIV Annual Congress of the European Society of Regional Anaesthesia and Pain Therapy to be held September 12 to 15, 2007 in Valencia, Spain.
The poster presents the results of a multi-centre, open-label, single-dose study examining Labopharm's once-daily formulation of tramadol (200 mg tablets) in patients with moderate to severe acute low back pain. The results of the study suggest that Labopharm's once-daily tramadol formulation provided therapeutic plasma concentrations and onset of analgesic effect within one hour, similar to that cited in the literature for the immediate-release tramadol product. The median duration to onset of pain relief was 45 minutes, at which time 78% of patients had moderate to complete pain relief (43% having a lot to complete pain relief and 35% having moderate pain relief).
"The rapid onset of analgesia suggested by the results of this study of our once-daily tramadol combined with the sustained 24-hour analgesia as demonstrated by our formulation in previous studies should provide a clinically significant benefit to patients," said James R. Howard-Tripp, President and Chief Executive Officer, Labopharm Inc.
The poster will be available on Labopharm's web site (http://www.labopharm.com) on Monday, September 17, 2007, following conclusion of the Congress.
Labopharm also announced today that an article discussing the positive
|SOURCE Labopharm Inc.|
Copyright©2007 PR Newswire.
All rights reserved